MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317167 | Name: Alizapride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Alizapride (Litican, Plitican, Superan, Vergentan) is a dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. It is structurally related to metoclopramide and other benzamides.

Chemical Structure

Alizapride
CAS#59338-93-1(free base)

Theoretical Analysis

MedKoo Cat#: 317167

Name: Alizapride

CAS#: 59338-93-1(free base)

Chemical Formula: C16H21N5O2

Exact Mass: 315.1700

Molecular Weight: 315.38

Elemental Analysis: C, 60.94; H, 6.71; N, 22.21; O, 10.15

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
59338-87-3 (HCl) 59338-93-1(free base)
Synonym
Alizapride; 59338-93-1; Limican; Plitican; Vergentan; Superan; Alizaprida; Litican; MS 5080; MS5080; MS-5080
IUPAC/Chemical Name
N-((1-allylpyrrolidin-2-yl)methyl)-6-methoxy-1H-benzo[d][1,2,3]triazole-5-carboxamide
InChi Key
KSEYRUGYKHXGFW-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H21N5O2/c1-3-6-21-7-4-5-11(21)10-17-16(22)12-8-13-14(19-20-18-13)9-15(12)23-2/h3,8-9,11H,1,4-7,10H2,2H3,(H,17,22)(H,18,19,20)
SMILES Code
O=C(C1=C(OC)C=C(NN=N2)C2=C1)NCC3N(CC=C)CCC3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 315.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Dewinter G, Teunkens A, Vermeulen K, Devroe S, Van Hemelrijck J, Meuleman C, Vergote I, Fieuws S, Van de Velde M, Rex S. Alizapride and ondansetron for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic gynaecological surgery: A double-blind, randomised, placebo- controlled noninferiority study. Eur J Anaesthesiol. 2016 Feb;33(2):96-103. doi: 10.1097/EJA.0000000000000288. PMID: 26086285. 2: Joss RA, Galeazzi RL, Bischoff AK, Brunner KW. Alizapride, a new substituted benzamide, as an antiemetic during cancer chemotherapy. Eur J Clin Pharmacol. 1985;27(6):721-5. doi: 10.1007/BF00547056. PMID: 3987777. 3: Bleiberg H, Gerard B, Dalesio O, Crespeigne N, Rozencweig M. Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial. Cancer Chemother Pharmacol. 1988;22(4):316-20. doi: 10.1007/BF00254238. PMID: 3048762. 4: Closset M, Goderniaux N, Colsoul ML, Soumoy L, Bihin B, Jamart J, Odou P, Hecq JD, Galanti L. Long term stability of an admixture of alizapride and ondansetron in 0.9% sodium chloride solution polyolefin bags stored at 5±3°C. J Oncol Pharm Pract. 2021 Sep;27(6):1328-1332. doi: 10.1177/1078155220950442. Epub 2020 Sep 9. PMID: 32903143. 5: Joss RA, Galeazzi RL, Bischoff AK, Pirovino M, Ryssel HJ, Brunner KW. The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial. Clin Pharmacol Ther. 1986 Jun;39(6):619-24. doi: 10.1038/clpt.1986.109. PMID: 3519041. 6: Booij LH, Rachmat S, Bulder ER. Alizapride in prevention of postoperative nausea and vomiting. Neth J Surg. 1988 Feb;40(1):6-9. PMID: 3281060. 7: Huys J, Troch M, Bourguignon RP, Smets P. High-dose alizapride versus high- dose domperidone: a double-blind comparative study in the management of cis- platinum-induced emesis. Curr Med Res Opin. 1985;9(6):400-6. doi: 10.1185/03007998509109611. PMID: 3886305. 8: Roché H, Hyman G, Nahas G, Stoopler M, Ellison R, Desjardins R. Comparative effects of intravenously administered alizapride and prochlorperazine in cisplatin-induced emesis. Cancer Invest. 1987;5(2):89-93. doi: 10.3109/07357908709018461. PMID: 3607576. 9: Vanacker B, Van Aken H. Alizapride in the prevention of postoperative vomiting. A double-blind comparison. Acta Anaesthesiol Belg. 1988;39(4):247-50. PMID: 3232497. 10: Pollera CF, Nardi M, Marolla P, Calabresi F. Alizapride alone or alizapride- dexamethasone compared with metoclopramide-dexamethasone in patients at high risk of acute emesis after cisplatin. A randomized cross-over study. Acta Oncol. 1991;30(6):725-9. doi: 10.3109/02841869109092447. PMID: 1958393. 11: Horta ML, Morejon LC, da Cruz AW, Dos Santos GR, Welling LC, Terhorst L, Costa RC, Alam RU. Study of the prophylactic effect of droperidol, alizapride, propofol and promethazine on spinal morphine-induced pruritus. Br J Anaesth. 2006 Jun;96(6):796-800. doi: 10.1093/bja/ael072. Epub 2006 Apr 5. PMID: 16597655. 12: Kauste A, Tuominen M, Heikkinen H, Gordin A, Korttila K. Droperidol, alizapride and metoclopramide in the prevention and treatment of post-operative emetic sequelae. Eur J Anaesthesiol. 1986 Jan;3(1):1-9. PMID: 3780685. 13: Warzee PL, Dive CC. Manometric study of the activity of alizapride on the motor function of the human sphincter of Oddi. J Clin Pharm Ther. 1988 Aug;13(4):281-4. doi: 10.1111/j.1365-2710.1988.tb00194.x. PMID: 3235478. 14: Aprile S, Del Grosso E, Grosa G. In vitro metabolic fate of alizapride: evidence for the formation of reactive metabolites based on liquid chromatography-tandem mass spectrometry. J Mass Spectrom. 2012 Jun;47(6):737-50. doi: 10.1002/jms.3011. PMID: 22707166. 15: Athanasopoulos A, Hecq JD, Vanbeckbergen D, Jamart J, Galanti L. Long-term stability of the hydrochlorides of tramadol and alizapride in dextrose 5% polyolefin bag at 5+/-3 degrees C. Ann Pharm Fr. 2010 May;68(3):157-62. doi: 10.1016/j.pharma.2010.03.004. Epub 2010 May 15. PMID: 20569772. 16: Colsoul ML, Hecq JD, Soumoy L, Charles O, Goderniaux N, Bihin B, Jamart J, Galanti L. Long-term stability of an infusion containing paracetamol, alizapride, ketorolac and tramadol in glass bottles at 5±3°C. Eur J Hosp Pharm. 2020 Mar;27(e1):e74-e78. doi: 10.1136/ejhpharm-2019-001966. Epub 2019 Jun 11. PMID: 32296510; PMCID: PMC7147551. 17: Niederle N, Schütte J, Schmidt CG. Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klin Wochenschr. 1986 Apr 15;64(8):362-5. doi: 10.1007/BF01728184. PMID: 3009962. 18: Debray H, Guihard J, Peyramond D, Tron P. Traitement des vomissements du nourrisson et de l'enfant liés à une pathologie infectieuse aiguë. Etude comparative alizapride versus métopimazine [Treatment of vomiting in infants and children induced by acute infectious pathology. A comparative study of alizapride versus metopimazine]. Ann Pediatr (Paris). 1990 Dec;37(10):683-7. French. PMID: 2291597. 19: Rey E, Stettler E, D'athis P, Pons G. Pharmacokinetics of alizapride in children receiving chemotherapy for solid tumour. Fundam Clin Pharmacol. 2001 Jun;15(3):217-20. doi: 10.1046/j.1472-8206.2001.00022.x. PMID: 11468033. 20: Simar J, Godet M, Hecq JD, Closset M, Gillet P, Langhendries C, Bihin B, Jamart J, Galanti L. Long-term stability of dexamethasone and alizapride or ondansetron in sodium chloride 0.9% polyolefin bag at 5±3°C. Ann Pharm Fr. 2017 Jan;75(1):30-39. doi: 10.1016/j.pharma.2016.08.001. Epub 2016 Sep 12. PMID: 27634586.